Ibrutinib
Medication used in cancer treatment
Summary
Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that inhibits B-cell proliferation and survival by irreversibly binding the protein Bruton's tyrosine kinase (BTK). Blocking BTK inhibits the B-cell receptor pathway, which is often aberrantly active in B cell cancers. Ibrutinib is therefore used to treat such cancers, including mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia. Ibrutinib also binds to C-terminal Src Kinases, which are off-target receptors for the BTK inhibitor. This binding inhibits the kinase from promoting cell differentiation and growth. Ibrutinib binds to these receptors and inhibits the kinase from promoting cell differentiation and growth. This leads to many different side effects like left atrial enlargement and atrial fibrillation during the treatment of Chronic Lymphocytic Leukemia.
Originally created by Edgar181
12/8/2011, 10:17:03 PM
Modified
2/12/2026, 12:10:17 AM
Recent revisions
cite repair;
Added article-number. Removed parameters. Some additions/deletions were parameter name changes. | [[:en:WP:UCB|Use this tool]]. [[:en:WP:DBUG|Report bugs]]. | #UCB_Gadget
Rescued 3 archive links. [[User:GreenC/WaybackMedic_2.5|Wayback Medic 2.5]] per [[WP:URLREQ#fda.gov]]
Reverted 1 edit by [[Special:Contributions/Abushamsuddin|Abushamsuddin]] ([[User talk:Abushamsuddin|talk]]): Rv apparent COI / citespam
/* Medical uses */ Added 2025 study on statin use and improved ibrutinib survival outcomes in CLL
dark mode fix
Added link
Rescuing 3 sources and tagging 0 as dead.) #IABot (v2.0.9.5) ([[User:Whywhenwhohow|Whywhenwhohow]] - 20275
update infobox, links
/* Economics */ IRA price neg mention
link acrylamide
Moving [[:Category:Johnson & Johnson brands]] to [[:Category:Drugs developed by Johnson & Johnson]] per [[Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands]]
Moving [[:Category:AbbVie brands]] to [[:Category:Drugs developed by AbbVie]] per [[Wikipedia:Categories for discussion/Log/2023 December 9#Category:AstraZeneca brands]]
Removing [[:Category:Breakthrough therapy]] per [[Wikipedia:Categories for discussion/Log/2023 November 20#Category:Breakthrough therapy]]
added [[Category:Small-molecule drugs]] using [[WP:HC|HotCat]]
